Page 266 - ASHG 2013 Program Guide

POSTER SESSIONS
  253
POSTER SESSIONS
W=W
ednesday authors will present; T=Thursday authors will present; F=Friday authors will pr
esent
3425
F Familial intracranial meningioma without
NF2
and
SUFU
mutations: Searching for additional predisposing
genes.
M. Aavikko, H. Ristolainen, E. Kaasinen, P. A.
Koivisto, M. Pöyhönen, K. Claes, T. Van Maerken, M.
Artama, E. Pukkala, L. A. Aaltonen, P. Vahteristo.
3426
W
DICER1
mutations in pituitary blastoma: New
gene, new disease.
L. de Kock, N. Sabbaghian, F.
Plourde, A. Srivastava, D. Bouron-Dal Soglio, N. Hamel, J.
H. Choi, S. H. Park, C. L. Deal, M. Dishop, A. Esbenshade,
T. Jacques, A. Perry, H. Leichter, P. Maeder, M. A. Brundler,
J. Neal, M. Zacharin, M. Korbonits, T. Cole, S. Albrecht, E.
Horvath, K. Kovacs, J. R. Priest, W. D. Foulkes.
3427
T Targeted sequencing of
MLH1
,
MLH2
,
and
MSH6
in defective mismatch repair colorectal cancer
cases with no identified mutation
M. DeRycke, S.
Gunawardena, S. McDonnell, S. Middha, S. Riska, Z.
Fogarty, B. Eckloff, D. Schaid, E. Goode, N. Lindor, S.
Thibodeau, Colon Cancer Family Registry.
3428
F Annotation of rare variants from exome
sequencing in families with lymphoid malignancies.
L.
R. Goldin, M. L. McMaster, M. Rotunno, J. He, L. Burdette,
A. Hutchinson, J. Boland, M. Yeager, M. A. Tucker, S. J.
Chanock, N. E. Caporaso.
3429
W Constitutional mismatch repair deficienc
syndrome caused my MMR gene founder mutations
with a high prevalence in Israel.
I. Kedar-Barnes, Z. Levi,
H. Toledano, M. Halpern, I. Lerer, T. Peretz, R. Kariv, E. Half,
N. Magal, K. Wimmer, Y. Goldberg, D. Berkovich, H. N. Baris.
3430
T Magnetic resonance imaging screening in Li
Fraumeni syndrome: An exploratory whole body MRI
study (the SIGNIFY study).
E. Killick, E. Bancroft, N.
Taylor, D. G. Evans, M. Leach, R. Eeles, The SIGNIFY
Collaborators and Steering Committee.
3431
F Characterization of
RB1
mutations and
incidence of undetected defects in retinoblastoma.
P.
S. Lai, A. P. Alcasabas, G. Sundar, B. L. Quah.
3432
W Exome sequencing of family with carcinoid
cancers.
D. W. Neklason, G. W. Gilcrease, N. R. Sargent,
A. Snow, C. Teerlink, M. Bailey, R. W. Burt.
3433
T Frequencies of
BRCA1
,
BRCA2
,
PALB2
,
and
CDKN2A
germline mutations in familial pancreatic
cancer: A PACGENE study.
D. B. Zhen, K. G. Rabe, S.
Gallinger, S. Syngal, A. G. Schwartz, M. G. Goggins, R.
H. Hruban, M. L. Cote, K. Moyes, R. J. Wenstrup, A. R.
Hartman, D. Seminara, A. P. Klein, G. M. Petersen.
3434
F Common somatic variations identified in
Maffucci syndrome.
M. Amyere, V. Wouters, A.
Dompmartin, O. Enjolras, I. Kaitila, P. L. Docquier, J. B.
Mulliken, L. M. Boon, V. Vikkula.
3435
W A survey of
HRAS
mutations in a large
cohort of patients with Costello syndrome reveals
a predisposition for embryonal rhabdomyosarcoma
with paternal uniparental disomy.
K. M. Robbins, D.
L. Stabley, A. Sadreameli, J. Holbrook, S. McCahan, R.
Sahraoui, K. W. Gripp, K. Sol-Church.
3412
T Investigation of resveratrol/AT-101’s molecular
targets of apoptotic effect to the hormone-sensitive
and hormone-nonsensitive prostate cancer cell lines.
Y. Yukselten, N. Aktepe, A. Kisim, H. Atmaca, B. Karaca.
3413
F Cytogenetic and FISH monitoring of t(16;21)
(
p11.2;q22)
FUS-ERG
fusion gene in an AML NOS
patient.
L. Militti, D. Fantasia, A. DiTecco, D. Onofrillo,
A. Spadano, G. Calabrese, G. Palka.
3414
W Intrafocal heterogeneity of gene
rearrangements in prostate cancer: Implications
to genomic targeting therapeutics.
I. Tereshchenko,
H. Zhong, U. Santanam, W. Petrosky, N. Kane-Goldsmith,
J. A. Tischfield, R. S. DiPaola.
3415
T Trisomy of chromosome 8 in children with
haematological malignancies.
D. Januszkiewicz-
Lewandowska, O. Zajac-Spychala, E. Maly, J. Nowak.
3416
F Joint effect of multiple common SNPs predicts
melanoma susceptibility in place of or beyond
traditional risk factors.
S. Fang, J. Han, M. Zhang,
L. Wang, Q. Wei, C. Amos, J. Lee.
3417
W Radiogenomics: Using genetics to identify
cancer patients at risk for development of adverse
effects following radiotherapy.
S. L. Kerns, H. Ostrer,
B. S. Rosenstein, Radiogenomics Consortium.
3418
T
RLIP76
expression levels in CML patients.
O. Altiok Clark, A. Toylu, O. Salim, A. Timuragaoglu,
M. Okur, OK. Yucel, N. Sayin Ekinci, M. Ulubahsi, K. Eker
Guler, I. Karadogan, L. Undar.
3419
F Circulating microRNAs in acute lymphoblastic
leukemia during chemotherapy treatment.
T. M. Marques, L. H. Sakamoto, C. P. C. Gomes, G. P.
Oliveira, Jr., G. R. Fernandes, R. W. Pereira.
3420
W microRNA expression profiling in metastati
cutaneous squamous cell carcinoma.
A. E. Toland,
L. E. Skeeles, S. B. Peters, T. Teknos, T. Olencki, D. C. Allain.
3421
T Prognostic significance of K-ras codon 12
mutation with resected gall bladder cancer.
H. R.
Kazmi, A. Chandra, D. Parmar, N. M.
3422
F Genetic polymorphisms in the apoptotic-
associated genes
Fas (-670 ag)
and Fas L (-844 tc) and
acute myeloid leukemia risk.
V. Sugunakar, C. Anuradha,
D. Nageswara rao, G. Manjula, E. M. Prajitha,
D. Raghnadharao, S. Sudha, A. Venkat Satya Suresh,
S. Vishnupriya.
3423
W TRAPing telomerase activity using droplet
digital PCR.
D. N. Shelton, J. Lin, J. F. Regan, G. Karlin-
Neumann, E. H. Blackburn.
3424
T Splicing of HRAS exon 2 is vulnerable: The
splicing efficiency of activating mutations in codons
12
and 13 determines Costello syndrome phenotype.
B. S. Andresen, A. M. Hartung, J. Swensen, I. E. Uriz, M.
Lapin, J. C. Carey, A. Calhoun, P. Yu, C. P. Vaughn, S. F.
Dobrowolski, M. R. Larsen, H. Hanson, D. A. Stevenson.